Northern VCTs Celebrate a Successful Exit with Gentronix
Northern 3 VCT PLC (“the Company”) is a leading Venture Capital Trust (VCT) that has been delivering impressive tax-free returns to its investors since it was established in 2001. This initiative is expertly managed by Mercia Fund Management Limited. The Company primarily invests in unquoted venture capital holdings, focusing on long-term capital growth and consistent dividend yields while ensuring compliance with tax regulations to maintain its VCT status.
Acquisition Details of Gentronix
In a significant development, Gentronix, a well-known contract research organization (CRO) specializing in genetic toxicology, has been acquired by the Scantox Group from Denmark. Although the financial specifics have not been disclosed, this acquisition represents a strategic exit for the Northern VCTs, which collectively realized £14.8 million from their investments in Gentronix, demonstrating a remarkable return on investment of 4.5x. Notably, Northern 3 VCT PLC secured £3.5 million from this exit, which will be reflected in their upcoming Net Asset Value announcements.
Growth of Gentronix
Founded in 1999 by Professor Richard Walmsley, Gentronix has made a significant impact in the pharmaceutical and chemical sectors by providing predictive toxicology services that assist clients in identifying genotoxic compounds early in their drug development processes. Based in Alderley Park, Cheshire, Gentronix has grown its workforce to nearly 70 employees, effectively doubling its size since 2021. The firm was recently awarded the King’s Award for Enterprise for tripling its overseas earnings in just three years, leading to an annual revenue surpassing £10 million, with an impressive 81% of sales coming from exports.
Future Prospects for Gentronix Under Scantox
Following the acquisition, Gentronix intends to continue its operations under its established name while leveraging Scantox Group's extensive network. This partnership is poised to unlock exciting global opportunities, allowing Scantox to enhance its service offerings in response to increasing client demand. Matt Tate, CEO of Gentronix, expressed his enthusiasm regarding the acquisition, emphasizing the unique opportunities this partnership presents for expanding their service portfolio and improving client offerings.
A Strategic Partnership for Growth
Alex Gwyther from Mercia Ventures highlighted the importance of patient capital in nurturing growth within high-potential businesses like Gentronix. The relationship between Northern VCTs and Gentronix dates back to 2007, reflecting a long-standing commitment to supporting the company’s success. Gwyther noted that this is an ideal time for Gentronix to embark on its next growth phase, aided by the promising collaboration with Scantox.
Scantox Group's Expansion Plans
The acquisition allows Scantox Group to expand its workforce, which is set to grow to nearly 400 employees across seven European locations. This strategic initiative not only enhances their capabilities in lead optimization and regulatory toxicology but also integrates Gentronix’s expertise into their growing suite of services. Jeanet Løgsted, CEO of Scantox Group, expressed her excitement about incorporating Gentronix's capabilities, effectively filling a significant gap in their service portfolio.
Conclusion
The acquisition of Gentronix marks a significant achievement for Northern 3 VCT PLC, reinforcing its position as a key player in the venture capital landscape. This strategic decision highlights the effectiveness of their long-term investment approach and sets the stage for Gentronix's enhanced growth trajectory within the Scantox Group. As these companies combine their strengths, the future looks promising for both, paving the way for innovative advancements in toxicology and pharmaceutical development.
Frequently Asked Questions
What is Northern 3 VCT PLC?
Northern 3 VCT PLC is a Venture Capital Trust that focuses on providing tax-free returns to investors through investments in unquoted venture capital holdings.
Who acquired Gentronix?
Gentronix was acquired by the Scantox Group, a contract research organization based in Denmark.
How much did the Northern VCTs gain from the Gentronix acquisition?
The Northern VCTs collectively gained £14.8 million from their investment in Gentronix, achieving a 4.5x return on investment.
What services does Gentronix provide?
Gentronix specializes in predictive toxicology services for the pharmaceutical and chemical industries, assisting clients in identifying potential genotoxic compounds.
What is Scantox Group's business focus?
Scantox Group focuses on toxicology and pharmaceutical development, offering a wide range of services, including lead optimization and regulatory toxicology.
